Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -461.14% is 219% below its 5-year average of -144.34%, near the low end of its 5-year range (-461.14%–-23.20%).
As of the fiscal period ended Tuesday, June 30, 2026. 70.05% below its 12-month average of -271.18%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -461.14%.
RETURN ON EQUITY (ROE)
-461.14%
RETURN ON EQUITY (ROE) AVG TTM
-271.18%
RETURN ON EQUITY (ROE) AVG 3Y
-234.28%
RETURN ON EQUITY (ROE) AVG 5Y
-144.34%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-70.05%
CURRENT VS 3Y AVG
-96.83%
CURRENT VS 5Y AVG
-219.48%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-997.70%
vs the sector median at left
Milestone Pharmaceuticals Inc.
Market Cap
$96.06M
Return on Equity (ROE)
-461.14%
TTM Avg
-271.18%
3Y Avg
-234.28%
5Y Avg
-144.34%
Market Cap
$96.58M
Return on Equity (ROE)
-11.85%
TTM Avg
-51.56%
3Y Avg
-105.39%
5Y Avg
-105.39%
Market Cap
$95.93M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$97.64M
Return on Equity (ROE)
-103.31%
TTM Avg
-140.03%
3Y Avg
-67.31%
5Y Avg
-49.97%
Market Cap
$97.52M
Return on Equity (ROE)
-584.65%
TTM Avg
-344.54%
3Y Avg
-57.14%
5Y Avg
-65.05%
Market Cap
$98.41M
Return on Equity (ROE)
-34.11%
TTM Avg
-78.33%
3Y Avg
-16.94%
5Y Avg
-8.09%
Market Cap
$101.28M
Return on Equity (ROE)
23.96%
TTM Avg
-4.38%
3Y Avg
-11.56%
5Y Avg
6.84%
Market Cap
$90.74M
Return on Equity (ROE)
-268.09%
TTM Avg
-238.76%
3Y Avg
-155.55%
5Y Avg
-124.74%
Market Cap
$88.66M
Return on Equity (ROE)
2.51%
TTM Avg
-5.84%
3Y Avg
-10.75%
5Y Avg
-7.81%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $96.06M | -461.14% | -271.18% | -234.28% | -144.34% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $96.58M | -11.85% | -51.56% | -105.39% | -105.39% |
| Conexeu Sciences Inc. (CNXU)vs › | $95.93M | N/A | N/A | N/A | N/A |
| Korro Bio, Inc. (KRRO)vs › | $97.64M | -103.31% | -140.03% | -67.31% | -49.97% |
| PolyPid Ltd. (PYPD)vs › | $97.52M | -584.65% | -344.54% | -57.14% | -65.05% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $98.41M | -34.11% | -78.33% | -16.94% | -8.09% |
| The Joint Corp. (JYNT)vs › | $101.28M | 23.96% | -4.38% | -11.56% | 6.84% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.74M | -268.09% | -238.76% | -155.55% | -124.74% |
| ImmuCell Corporation (ICCC)vs › | $88.66M | 2.51% | -5.84% | -10.75% | -7.81% |
| electroCore, Inc. (ECOR)vs › | $91.15M | N/A | 329.82% | 69.21% | 21.28% |
ROE
-461.1%
ROA
-46.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -461.14% |
| 2026-03-31 | -189.64% |
| 2025-12-31 | -150.97% |
| 2025-09-30 | -282.97% |
| 2024-12-31 | -315.81% |
| 2024-09-30 | -178.11% |
| 2024-06-30 | -151.38% |
| 2024-03-31 | -138.00% |
| 2023-12-31 | -355.88% |
| 2023-09-30 | -207.87% |
| 2023-06-30 | -145.33% |
| 2023-03-31 | -110.00% |
| 2022-12-31 | -88.00% |
| 2022-09-30 | -80.48% |
| 2022-06-30 | -71.27% |
| 2022-03-31 | -44.01% |
| 2021-12-31 | -38.06% |
| 2021-09-30 | -27.18% |
| 2021-06-30 | -23.20% |
| 2021-03-31 | -34.96% |
| 2020-12-31 | -34.91% |
| 2020-09-30 | -58.31% |
| 2020-06-30 | -68.67% |
| 2020-03-31 | -61.35% |
| 2019-12-31 | -48.06% |
| 2019-09-30 | -35.13% |
| 2019-06-30 | -27.20% |
